NCT05113966 2025-01-29Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast CancerG1 Therapeutics, Inc.Phase 2 Terminated30 enrolled 16 charts
NCT01631552 2021-08-12Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial CancerGilead SciencesPhase 1/2 Completed515 enrolled 28 charts 2 FDA